Systemic pyoderma gangrenosum responding to infliximab and adalimumab
- Resource Type
- Authors
- V. G. Hubbard; A.C. Friedmann; P. Goldsmith
- Source
- British Journal of Dermatology. 152:1059-1061
- Subject
- Adult
Male
medicine.medical_specialty
Constitutional symptoms
medicine.medical_treatment
Dermatology
Disease
Leg Dermatoses
Antibodies, Monoclonal, Humanized
Pharmacotherapy
medicine
Adalimumab
Humans
skin and connective tissue diseases
Chemotherapy
business.industry
Antibodies, Monoclonal
medicine.disease
Infliximab
Pyoderma Gangrenosum
Monoclonal
Immunology
Drug Therapy, Combination
Dermatologic Agents
business
Pyoderma gangrenosum
medicine.drug
- Language
- ISSN
- 1365-2133
0007-0963
Pyoderma gangrenosum (PG) is frequently associated with constitutional symptoms as part of a nonspecific inflammatory response. However, extracutaneous discrete aseptic neutrophilic infiltrates are extremely rare. We report a patient with idiopathic PG with splenic and psoas muscle involvement. His disease was extremely aggressive and was unresponsive to conventional immunosuppressive therapy. His cutaneous and extracutaneous PG cleared with infliximab and adalimumab.